ClinicalTrials.gg
CompletedNCT00848926Updated Mar 13, 2017Results posted

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

A Phase 2 interventional study of brentuximab vedotin in Disease, Hodgkin, sponsored by Seagen Inc.. Completed at 27 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
19th of 80
102 · median 52
Started
2009
with 2 others
Phase 2
41 of 80
8 open now
Registered
3rd of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 19th largest by enrollment, is one of 3 that started in 2009, is one of 41 in phase 2, and was the 3rd registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

03

Conditions studied

  • Disease, Hodgkin

Keywords

  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Disease, Hodgkin
  • Hematologic Diseases
  • Lymphoma
  • monomethylauristatin E
  • Drug Therapy
  • Immunotherapy
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Hodgkin lymphoma who have previously received stem cell transplant.
  • confirmed CD30-positive disease; tissue from the most recent post diagnostic of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.
  • Fluorodeoxyglucose-avid disease by positron emission tomography and of at least 1.5 cm as documented by spiral computed tomography.
  • At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with brentuximab vedotin.
  • Previously received an transplant.
  • Congestive heart failure, Class III or IV, by the criteria.
  • History of another primary that has not been in remission for at least 3 years.
  • Known cerebral/meningeal disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin

    Drug: brentuximab vedotin

Interventions

  • 1.8 mg/kg every 3 weeks by intravenous infusion

    Also known as: SGN-35, ADCETRIS

06

What researchers measure

Primary outcomes

  1. Objective Response Rate by Independent Review Group

    Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: up to 12 months

Secondary outcomes

  1. Complete Remission Rate by Independent Review Group

    Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: up to 12 months

  2. Duration of Objective Response by Kaplan-Meier Analysis

    Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.

    Time frame: up to approximately 4 years

  3. Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis

    Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.

    Time frame: up to approximately 4 years

  4. Progression-free Survival by Kaplan-Meier Analysis

    Time from start of study treatment to disease progression per independent review group or death due to any cause.

    Time frame: up to approximately 4 years

  5. Overall Survival

    Time from start of study treatment to date of death due to any cause.

    Time frame: up to approximately 6 years

  6. Adverse Events by Severity, Seriousness, and Relationship to Treatment

    Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: up to 12 months

  7. Hematology Laboratory Abnormalities >/= Grade 3

    Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

    Time frame: up to 12 months

  8. Chemistry Laboratory Abnormalities >/= Grade 3

    Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

    Time frame: up to 12 months

  9. Area Under the Curve

    Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  10. Maximum Serum Concentration

    Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  11. Time of Maximum Serum Concentration

    Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

Other outcomes

  1. B Symptom Resolution

    Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

    Time frame: up to 12 months

07

Results

Posted Oct 26, 2011

Participant flow

Enrollment period: Feb 2009 - Aug 2009

Treatment Period
Participant flow — Treatment Period
MilestoneBrentuximab Vedotin
Started102
Completed18
Not completed84
Withdrew: Progressive disease45
Withdrew: Adverse event20
Withdrew: Physician decision12
Withdrew: Withdrawal by subject7
Follow-up Period
Participant flow — Follow-up Period
MilestoneBrentuximab Vedotin
Started102
Completed90
Not completed12
Withdrew: Lost to follow-up7
Withdrew: Withdrawal by subject3
Withdrew: Other2

Outcome measures

PrimaryObjective Response Rate by Independent Review Group

Percentage of participants who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
Objective Response Rate by Independent Review Group
percent of participantsBrentuximab Vedotin
Objective Response Rate by Independent Review Group75 (64.9 to 82.6)
SecondaryComplete Remission Rate by Independent Review Group

Percentage of participants who achieved a best response of CR (disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
Complete Remission Rate by Independent Review Group
percent of participantsBrentuximab Vedotin
Complete Remission Rate by Independent Review Group33 (24.3 to 43.4)
SecondaryDuration of Objective Response by Kaplan-Meier Analysis

Duration of objective response (CR + PR) by independent review group, defined as time of initial response until disease progression or death.

Time frame:
up to approximately 4 years
Reported as:
Median · months
Duration of Objective Response by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Duration of Objective Response by Kaplan-Meier Analysis6.7 (3.6 to 14.8)
SecondaryDuration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis

Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.

Time frame:
up to approximately 4 years
Reported as:
Median · months
Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis27.9 (10.8 to NA)
SecondaryProgression-free Survival by Kaplan-Meier Analysis

Time from start of study treatment to disease progression per independent review group or death due to any cause.

Time frame:
up to approximately 4 years
Reported as:
Median · months
Progression-free Survival by Kaplan-Meier Analysis
monthsBrentuximab Vedotin
Progression-free Survival by Kaplan-Meier Analysis5.6 (5.0 to 9.0)
SecondaryOverall Survival

Time from start of study treatment to date of death due to any cause.

Time frame:
up to approximately 6 years
Reported as:
Median · months
Overall Survival
monthsBrentuximab Vedotin
Overall Survival40.5 (28.7 to 61.9)
SecondaryAdverse Events by Severity, Seriousness, and Relationship to Treatment

Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
up to 12 months
Reported as:
Number · participants
Adverse Events by Severity, Seriousness, and Relationship to Treatment
participantsBrentuximab Vedotin
Any TEAE100
TEAE related to study drug94
TEAE with severity grade >/=356
Serious adverse event25
Serious adverse event related to study drug14
Discontinued treatment due to adverse event20
SecondaryHematology Laboratory Abnormalities >/= Grade 3

Counts of study participants with post-baseline hematology laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Time frame:
up to 12 months
Reported as:
Number · participants
Hematology Laboratory Abnormalities >/= Grade 3
participantsBrentuximab Vedotin
Any >/= Grade 3 hematology laboratory abnormality35
Hemoglobin (low)7
Leukocytes (low)6
Lymphocytes (low)20
Neutrophils (low)12
Platelets (low)7
SecondaryChemistry Laboratory Abnormalities >/= Grade 3

Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Time frame:
up to 12 months
Reported as:
Number · participants
Chemistry Laboratory Abnormalities >/= Grade 3
participantsBrentuximab Vedotin
Any >/= Grade 3 chemistry laboratory abnormality14
Alanine aminotransferase (high)1
Albumin (low)1
Calcium (low)1
Glucose (high)7
Potassium (low)2
Sodium (high)1
Urate (high)1
SecondaryArea Under the Curve

Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · day * microgram/mL
Area Under the Curve
day * microgram/mLBrentuximab Vedotin
Area Under the Curve88 ± 46
Other pre-specifiedB Symptom Resolution

Percentage of participants with lymphoma-related symptoms (B symptoms: fever, night sweats, or weight loss \>10%) at baseline who achieved resolution of all B symptoms at any time during the treatment period.

Time frame:
up to 12 months
Reported as:
Number · percent of participants
B Symptom Resolution
percent of participantsBrentuximab Vedotin
B Symptom Resolution77 (59.9 to 89.6)
SecondaryMaximum Serum Concentration

Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · microgram/mL
Maximum Serum Concentration
microgram/mLBrentuximab Vedotin
Maximum Serum Concentration35 ± 17
SecondaryTime of Maximum Serum Concentration

Time of maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Median · days
Time of Maximum Serum Concentration
daysBrentuximab Vedotin
Time of Maximum Serum Concentration0.02 (0.02 to 0.02)

Adverse events

Collected over Treatment-emergent adverse events through 30 days after last dose (up to 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin—25/102 (24.5%)97/102 (95.1%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventBrentuximab Vedotin
Abdominal painGastrointestinal disorders2/102
PyrexiaGeneral disorders2/102
PyelonephritisInfections and infestations2/102
Demyelinating polyneuropathyNervous system disorders2/102
PneumonitisRespiratory, thoracic and mediastinal disorders2/102
PneumothoraxRespiratory, thoracic and mediastinal disorders2/102
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/102
ThrombocytopeniaBlood and lymphatic system disorders1/102
Abdominal pain upperGastrointestinal disorders1/102
DiarrhoeaGastrointestinal disorders1/102
Most frequent other events
Showing 10 of 45
Most frequent other events
EventBrentuximab Vedotin
Peripheral sensory neuropathyNervous system disorders48/102
FatigueGeneral disorders47/102
NauseaGastrointestinal disorders43/102
Upper respiratory tract infectionInfections and infestations38/102
DiarrhoeaGastrointestinal disorders37/102
PyrexiaGeneral disorders30/102
NeutropeniaBlood and lymphatic system disorders22/102
VomitingGastrointestinal disorders22/102
CoughRespiratory, thoracic and mediastinal disorders21/102
ArthralgiaMusculoskeletal and connective tissue disorders19/102

Baseline characteristics

Age, Customized
Age, Customized(years)Brentuximab Vedotin
Median31.0 (15 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin
Female54
Male48
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American5
White89
More than one race0
Unknown or Not Reported1
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Brentuximab Vedotin
042
160
2-50
08

Study locations

27 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • City of Hope National Medical Center
    Duarte, California 91010-3000, United States
  • University of California at Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Loyola University Medical Center Cardinal Bernardin Cancer Center
    Maywood, Illinois 60153, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • Cliniques Universitaires UCL de Mont-Goddine
    Yvoir, 5530, Belgium
  • B.C Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Hospital Saint Louis
    Paris, 75475, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Instituto di Ematologia ed Oncologia Medica
    Bologna, 40138, Italy
09

References and documents

Publications

  • Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. PubMed 22454421 ↗
  • Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18. PubMed 27432875 ↗
  • Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19;125(8):1236-43. doi: 10.1182/blood-2014-08-595801. Epub 2014 Dec 22. PubMed 25533035 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Aug 2010 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2009
First posted
Feb 20, 2009
Start
Feb 2009
Primary completionActual
Aug 2010
CompletionActual
May 2015
Results first posted
Oct 26, 2011
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00848926
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Feb 20, 2009
Start date
Feb 2009
Primary completion
Aug 2010
Completion
May 2015
Results posted
Oct 26, 2011
Last update
Mar 13, 2017

Study contacts

Abraham Fong, MD, PhD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion